{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:01:17Z","timestamp":1788627677055,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to delineate the temporal tendency in the age and gender burden of psoriasis in China, spanning from 1990 to 2021, encompassing metrics such as incidence, prevalence, and disability-adjusted life years (DALYs). Furthermore, it sought to contrast these findings with the global disease burden. It also purposed to assess the impacts of age, time, and birth cohort, as well as to forecast the psoriasis burden in China for the upcoming 15\u202fyears.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Utilizing open-access data from the Global Burden of Disease (GBD) database spanning 1990 to 2021, this study comprehensively examined the burden of psoriasis in China and globally. In China, a detailed analysis was conducted, emphasizing dimensions such as age, gender, and temporal trends. Join-point regression models were employed to calculate the average annual percentage change (AAPC). Furthermore, age-period-cohort (APC) analyses assessed the effects of age, time, and birth cohort, while an extended autoregressive integrated moving average model (ARIMA model) was used to forecast the psoriasis burden in China from 2022 to 2036.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 1990 and 2021, China experienced significant changes in its age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALY Rate (ASDR). Specifically, the ASIR rose from 48 per 100,000 in 1990 to 60 per 100,000 in 2021. Correspondingly, the ASPR increased from 362 per 100,000 in 1990 to 474 per 100,000 in 2021. Finally, the ASDR also showed an upward trend, climbing from 31 per 100,000 in 1990 to 41 per 100,000 in 2021. The AAPC of the ASIR, ASPR, and ASDR in China was 0.7434%, 0.8765%, and 0.8827%, respectively, significantly outpacing the global AAPC of 0.2204%, 0.2220%, and 0.2426%, respectively. The burden of psoriasis in China varied with age and gender, showing a trend of increasing and then decreasing ASIR, ASPR, and ASDR as age advanced. Women experienced lower incidence and prevalence rates of psoriasis than men. Over time, a delay in peak incidence was observed in both genders. The APC analyses revealed that psoriasis incidence initially increased and then declined with advancing age. Across all age groups, earlier birth cohorts had a relatively lower risk. Projections suggest that the incidence and prevalence of psoriasis in China will continue to rise over the next 15\u202fyears.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psoriasis poses a substantial public health challenge in China due to the country\u2019s large and increasingly aging populace. Mitigating this burden requires a multifaceted approach, including precise epidemiological research, an enhanced understanding of its socioeconomic determinants, and the development of effective health policies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1541292","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:11:15Z","timestamp":1741219875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021"],"prefix":"10.3389","volume":"13","author":[{"given":"Keyi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilong","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22094529","article-title":"Psoriasis and gut microbiome\u2014current state of art","volume":"22","author":"Polak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/bjd.13715","article-title":"The global burden of psoriatic skin disease","volume":"172","author":"Goff","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","article-title":"Evaluating the economic burden of psoriasis in the United States","volume":"72","author":"Vanderpuye-Orgle","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jaad.2008.06.043","article-title":"The impact of psoriasis on health care costs and patient work loss","volume":"59","author":"Fowler","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000093848","article-title":"Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis","volume":"213","author":"Schmitt","year":"2006","journal-title":"Dermatology"},{"key":"ref7","first-page":"429","article-title":"Quantifying the burden of disease: the technical basis for disability-adjusted life years","volume":"72","author":"Murray","year":"1994","journal-title":"Bull World Health Organ"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.scitotenv.2015.05.017","article-title":"Assessing burden of disease as disability adjusted life years in life cycle assessment","author":"Kobayashi","year":"2015","journal-title":"Sci Total Environ"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00403-024-02846-z","article-title":"Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030","volume":"316","author":"Wang","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of Disease study 2021","volume":"403","author":"Diseases","year":"2024","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of Disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s13524-013-0243-z","article-title":"Assessing validity and application scope of the intrinsic estimator approach to the age-period-cohort problem","volume":"50","author":"Luo","year":"2013","journal-title":"Demography"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cac2.12099","article-title":"The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990-2017","volume":"40","author":"Liu","year":"2020","journal-title":"Cancer Commun"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"652868","DOI":"10.3389\/fpubh.2021.652868","article-title":"Long-term changes of HIV\/AIDS Incidence rate in China and the U.S. population from 1994 to 2019: a join-point and age-period-cohort Analysis","volume":"9","author":"Ma","year":"2021","journal-title":"Front Public Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-021-01235-8","article-title":"Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions","volume":"21","author":"Schaffer","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-210225","article-title":"The Burden of Alzheimer's Disease Mortality in the United States, 1999\u20132018","volume":"82","author":"Zhao","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2147\/DDDT.S92128","article-title":"Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy","volume":"11","author":"Giunta","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4155\/tde-2017-0058","article-title":"Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature","volume":"8","author":"Frieder","year":"2017","journal-title":"Ther Deliv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.19169","article-title":"Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*","volume":"184","author":"Iskandar","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/ced.14218","article-title":"Sex-and gender-associated clinical and psychosocial characteristics of patients with psoriasis","volume":"45","author":"Napolitano","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jaad.2016.10.040","article-title":"Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis","volume":"76","author":"Hawro","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of Disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0140-6736(17)30818-8","article-title":"Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990\u20132015: a novel analysis from the Global Burden of Disease Study 2015","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/pde.12351","article-title":"A systematic review of systemic medications for pustular psoriasis in pediatrics","volume":"31","author":"Posso-De Los Rios","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e028116","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1541292\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:11:17Z","timestamp":1741219877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1541292\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":28,"alternative-id":["10.3389\/fpubh.2025.1541292"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1541292","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"article-number":"1541292"}}